Levocetirizine: Nursing Drug Guide, Renal Dosing & NCLEX Review

Levocetirizine dihydrochloride is the active R-enantiomer of cetirizine—a selective peripheral H₁-receptor antagonist. U.S. products include scored tablets and oral solution; always match dose to formulation and prescribing information.

• Tablets: Xyzal; multiple generic 5 mg scored film-coated tablets (may be split for 2.5 mg)
• Oral solution: Per product label—pediatric strengths; verify mL-to-mg conversion on the bottle
• Not interchangeable with: racemic cetirizine (Zyrtec) on strength or renal table—cross-allergy contraindication
• Not interchangeable with: sedating first-generation agents such as diphenhydramine

Per U.S. levocetirizine dihydrochloride tablet prescribing information:

• Chronic idiopathic urticaria: Treatment of uncomplicated skin manifestations in adults and children 6 years and older

Some oral-solution labeling includes additional pediatric indications (for example perennial allergic rhinitis in young children)—verify the exact product label in hand. Nurses commonly manage hives, pruritus, and nasal congestion with antihistamines but must not substitute levocetirizine for anaphylaxis treatment.

Levocetirizine is an orally active, selective H₁-receptor antagonist and the R-enantiomer of cetirizine. It blocks peripheral histamine H₁ receptors, reducing histamine-mediated vasodilation, pruritus, and wheal-and-flare responses.

Labeling warns that levocetirizine is associated with somnolence, fatigue, and asthenia and advises avoiding hazardous activities requiring complete mental alertness. Unlike first-generation antihistamines, anticholinergic activity is low in animal models, but dry mouth and urinary retention still occur in clinical use and postmarketing reports.

Oral route only. U.S. tablets are 5 mg scored—may be split for 2.5 mg. May be taken without regard to food per prescribing information.

Standard dosing (U.S. tablet labeling)

↔On a small screen, swipe or scroll sideways to see the full table.

Renal dose adjustment — adults and children 12+ (mandatory per U.S. labeling)

↔On a small screen, swipe or scroll sideways to see the full table.

No dose adjustment for hepatic impairment alone; adjust when both hepatic and renal impairment are present per labeling. Children 6 months to 11 years with renal impairment: use is contraindicated.

• Absorption: Rapid; peak plasma concentration ~0.9 hour after oral tablet
• Food: May be taken with or without food; high-fat meals may delay T_max and lower C_max per labeling
• Half-life: Prolonged as renal function declines—dose and interval must follow creatinine clearance
• Elimination: Substantially renally excreted; total body clearance correlates with creatinine clearance
• Dialysis: Less than 10% removed during a standard 4-hour hemodialysis procedure—dialysis is not an effective removal strategy for overdose

Answer these before the first dose or when renal function or home meds change:

• Correct patient, drug (levocetirizine not racemic cetirizine), strength (2.5 mg vs 5 mg), route, and evening schedule
• Creatinine clearance or eGFR — match dose to renal table; hold if CL_CR <10 mL/min or on hemodialysis
• No duplicate antihistamine — including cetirizine, loratadine, fexofenadine, or diphenhydramine
• History of hypersensitivity to levocetirizine or cetirizine
• Urinary retention risk — spinal cord lesion, prostatic hyperplasia, or new inability to void
• Recent alcohol or CNS depressants — labeling advises avoiding concurrent use
• Occupation requiring alertness (driving, machinery)
• Pregnancy or breastfeeding — insufficient human pregnancy data per labeling; LactMed supports cautious use when needed—monitor infant for sedation

• Known hypersensitivity to levocetirizine, any ingredient, or cetirizine (reactions range from urticaria to anaphylaxis per labeling)
• End-stage renal disease — creatinine clearance <10 mL/min
• Hemodialysis
• Children 6 months to 11 years with renal impairment

↔On a small screen, swipe or scroll sideways to see the full table.

No clinically significant interaction with azithromycin, erythromycin, ketoconazole, theophylline, or pseudoephedrine was observed at therapeutic doses in labeling studies.

• Give in the evening when ordered once daily per standard labeling
• 5 mg scored tablets may be broken for 2.5 mg doses—verify partial-tablet policy
• Use calibrated device for oral solution—confirm mg per mL on label
• Document creatinine-based dose verification and 24-hour antihistamine total

• Reduced urticarial lesions and pruritus over hours to days
• Onset of histamine wheal suppression within ~1 hour; effect persists ≥24 hours at labeled doses in pharmacodynamic studies
• If symptoms persist at maximum labeled dose, prescriber may adjust therapy—not by adding racemic cetirizine on top of levocetirizine

• Anaphylaxis or serious hypersensitivity (urticaria with angioedema, bronchospasm, hypotension)—postmarketing anaphylaxis reported; stop drug and treat per emergency pathway
• Urinary retention—inability to void, suprapubic discomfort, or rising post-void residual; discontinue per labeling
• Severe somnolence or confusion—especially with alcohol or CNS depressants
• Ordered dose inconsistent with current creatinine clearance

Common adverse reactions (≥2% and greater than placebo) per U.S. prescribing information:

↔On a small screen, swipe or scroll sideways to see the full table.

Postmarketing: anaphylaxis, urinary retention, aggression, convulsions, visual disturbances, and others—report per facility policy.

Per prescribing information, overdose symptoms may include drowsiness in adults. In children, agitation and restlessness may occur first, followed by drowsiness.

Antidote

No known specific antidote. Provide symptomatic and supportive treatment; consider co-ingestants.

• Levocetirizine is not effectively removed by dialysis unless another dialyzable agent was taken
• Secure oral tablets and solution—pediatric ingestion causes serious CNS effects

• Levocetirizine vs cetirizine — different mg strengths and renal tables; cetirizine allergy contraindicates levocetirizine
• Xyzal vs Zyrtec — brand confusion leads to duplicate enantiomer exposure
• 5 mg vs 2.5 mg — renal patients often need half-tablet doses—verify scored-tablet splitting
• Evening-only scheduling — do not move to morning without prescriber order when sedation is a concern
• Hospital formulary vs home bottle — reconcile at admission

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Creatinine / eGFR trend and dose alignment with renal table
• Sedation, fatigue, and ability to perform alertness-dependent tasks
• Urinary output and retention symptoms in at-risk patients
• Pruritus and urticaria control
• Signs of hypersensitivity after first doses

Document

• Dose, strength (2.5 mg vs 5 mg), time, and creatinine clearance used for dose verification
• Basic metabolic panel / renal labs reviewed
• Duplicate antihistamine reconciliation (including cetirizine products)
• Voiding pattern when retention risk factors present

• Take exactly as prescribed—renal disease may require half tablets or less frequent dosing
• Do not take cetirizine (Zyrtec) while on levocetirizine (Xyzal) unless prescriber approves
• Drowsiness can occur—avoid alcohol, sedatives, and driving if sleepy
• Report inability to urinate, severe dizziness, or breathing difficulty immediately
• Bring all allergy bottles to visits—many patients do not know Xyzal and Zyrtec are related
• Keep medication locked away from children

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for levocetirizine using a tabbed case (MAR, labs, history, nursing notes), then priority action, select-all-that-apply cues, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes (mandatory creatinine-based dosing, cetirizine duplication, urinary retention, and sedation stacking).

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.